Table 3.
Univariate analysis between clinicopathological parameters and survival
| Parameters | Cases | 5-year DFS (%) | P value | 5-year OS(%) | P value |
|---|---|---|---|---|---|
| Age | |||||
| <60 | 94 | 54.8 | 0.581 | 60.2 | 0.339 |
| ≥60 | 78 | 57.2 | 67.5 | ||
| Sex | |||||
| Male | 112 | 57.5 | 0.373 | 66.9 | 0.172 |
| Female | 60 | 52.9 | 54.9 | ||
| Differentiation | |||||
| Low | 67 | 50.1 | 0.062 | 61.2 | 0.095 |
| Moderate | 72 | 52.3 | 60.6 | ||
| High | 33 | 75.6 | 78.2 | ||
| Pathology | |||||
| Squamous | 72 | 62.1 | 0.189 | 70.5 | 0.175 |
| Non-squamous | 100 | 51.4 | 57.6 | ||
| Pathological tumor status | |||||
| T1 | 38 | 78.4 | 0.004 | 81.6 | 0.004 |
| T2 | 112 | 50.7 | 59.4 | ||
| T3 | 22 | 43.6 | 48.5 | ||
| Pathological node status | |||||
| N0 | 106 | 72.1 | <0.001 | 77.2 | <0.001 |
| N1 | 31 | 41.9 | 50.6 | ||
| N2 | 35 | 20.0 | 30.8 | ||
| CD133 | |||||
| Negative | 86 | 59.9 | 0.359 | 67.1 | 0.133 |
| Positive | 86 | 51.9 | 58.7 | ||
| OCT-4 | |||||
| Negative | 75 | 64.9 | 0.063 | 70.5 | 0.047 |
| Positive | 97 | 48.9 | 56.9 | ||
| CD8 | |||||
| Low expression | 86 | 41.0 | <0.001 | 47.5 | <0.001 |
| High expression | 86 | 70.7 | 78.5 | ||
| CD56 | |||||
| Low expression | 86 | 51.7 | 0.315 | 57.5 | 0.084 |
| High expression | 86 | 60.1 | 68.4 | ||
| HLA I | |||||
| Negative | 17 | 35.3 | 0.009 | 41.2 | 0.010 |
| Moderate | 127 | 52.9 | 61.9 | ||
| Positive | 28 | 82.1 | 89.3 | ||
| PD-L1 (10%) | |||||
| Low expression | 120 | 59.6 | 0.172 | 67.1 | 0.033 |
| High expression | 52 | 47.3 | 53.2 | 0.036 | |
| PD-L1 (1%) | |||||
| Low expression | 58 | 48.7 | 0.278 | 56.1 | 0.336 |
| High expression | 114 | 59.4 | 62.0 | ||
| CD133 CD56 | |||||
| CD133 low and CD56 high | 59 | 63.9 | 0.141 | 74.4 | 0.013 |
| CD133 high and/or CD56 low | 113 | 51.8 | 57.1 | ||
| OCT-4 CD56 | |||||
| OCT-4 low and CD56 high | 50 | 65.5 | 0.114 | 71.9 | 0.098 |
| OCT-4 high and/or CD56 low | 122 | 51.3 | 59.2 |